Intellia Therapeutics Inc (FRA:38I)
€ 21.68 -0.35 (-1.59%) Market Cap: 2.05 Bil Enterprise Value: 1.42 Bil PE Ratio: 0 PB Ratio: 2.16 GF Score: 59/100

Intellia Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2020 / 07:20PM GMT
Release Date Price: €10.96 (+2.96%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Thank you, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. I first hope that everyone stay healthy, and I would like to thank all the participants, investors and companies, and especially our event team and corporate access team who made this virtual health care conference possible.

With that, I would like to introduce our next presenter, John Leonard, President and the Chief Executive Officer from Intellia. Hi, John.

John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Hi, Gena. How are you?

Huidong Wang;John M. Leonard
Barclays Bank PLC, Research Division - Research Analyst;Intellia

Good, good. Maybe I will start with more of the big picture question. I know you don't have a slide for investors. Maybe wondering if you could just give us a quick overview of Intellia, so that would be helpful for those investors who are not familiar with the company.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot